LILRB3 suppresses immunity in glioma and is associated with poor prognosis.

Based on immunohistochemistry (IHC) staining, only 5% of glioma tissues with low LILRB3 expression exhibited high PD-1 expression, while both low and high PD-1 expression was observed in high-LILRB3-expression samples (Figure 3D,E and Figure S7A). Samples with high expression or median expression of LILRB3 are classified into high LILRB3 group for Chi-square analysis. This finding is in line with previous reports demonstrating that LILRB3 can interact with SHP-1 in 293T cells.[10] Moreover, high expression of APOE shows a lower T cell activation expression pattern in GBM (Figure 2Q). [Extracted from the article]